|
|
10165 McKeller Court
San Diego, CA 92121 USA
phone:858- 552-1100
fax:(858) 453-4338
|
|
| Symbol |
QDEL |
| Exchange |
NASDAQ GS |
| Founded |
1979 |
| Employees |
300 |
|
|
| www.quidel.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Point-of-care rapid diagnostic tests. |
|
| Management |
| Mark A. Pulido, Chairman of the Board; Caren L. Mason, President and Chief Executive Officer; Thomas D. Brown, Retired Senior Vice President and President of the Diagnostics Division of Abbott Laboratories; Rod F. Dammeyer, President, CAC, LLC; Mary Lake Polan, Professor and Chair Emeritus; Jack W. Schuler, Chairman of the Board Stericycle, Inc.; Kenneth F. Buechler, Founder and Former Chief Scientific Officer Biosite Incorporated; |
| |
|
|
|
|
|
|
|
| Keywords |
| rapid diagnostics, reproduction, elderly, diseases, infectious, diseases, women's, women, health, colorectal, cancer, advamed |
|
|
|
| Description |
|
Quidel Corporation discovers, develops, manufactures and markets rapid diagnostic solutions at the point of care (POC) in infectious diseases, reproductive health, bone health and oncology. Quidel Corporation through their rapid tests and specialty products group product lines focus on the discovery, development, manufacturing and marketing of clinical diagnostic kits and unique research products in the fields of infectious disease, bone metabolism, oncology, and women's health. Quidel provides POC and diagnostic tests under the brand names QuickVue (R) , QuickVue+ (R) , QuickVue Advance (R) , RapidVue (R) , MicroVue(TM) and Metra ( R) . The company offers POC diagnostics products for infectious diseases, such as Influenza, Group A Strep, Helicobacter pylori, and Mononucleosis; Reproductive Health, which include Pregnancy, Chlamydia, and Bacterial Vaginosis; and Bone Health and Oncology. |
|
| Products / Services |
Quidel Corporation through their rapid tests and specialty products group product lines focus on the discovery, development, manufacturing and marketing of clinical diagnostic kits and unique research products in the fields of infectious disease, bone metabolism, oncology, and women's health. Quidel provides POC and diagnostic tests under the names QuickVue, QuickVue+, QuickVue Advance, RapidVue, and Metra. The company offers POC diagnostics products for infectious diseases, such as Influenza, Group A Strep, Helicobacter pylori, and Mononucleosis; Reproductive Health, which include Pregnancy, Chlamydia, and Bacterial Vaginosis; and Bone Health and Oncology.
|
|
| Technology / Differentiation |
| The rapid diagnostic products are sold to healthcare professionals with a focus on the physician office lab and acute care markets, allowing for patient testing out of the central laboratory setting and into the physician office. Quidel has established partnerships with medical advisors, government agencies, professional societies and has formed three Medical Advisory Boards for insights into the areas of expertise. |
|
| Market / Customers |
Physician offices, hospitals, clinical laboratories, physician office laboratories, student health canters, long term care facilities, retail clinics and corporate wellness centers are within the scope of Quidel's market. The worldwide market for in vitro diagnostic, or IVD, products was estimated at approximately $28.0 billion in 2005, and is segmented by the particular test discipline. The largest market segments are immunodiagnostics testing and instrument-based clinical chemistry, which account for approximately 31% and 21% of the total IVD market, respectively. Geographically, in 2006, approximately 40% of total IVD revenues were generated in the U.S., while Europe and Asia accounted for approximately 37% and 18%, respectively. Customers for IVD products are primarily large centralized laboratories, independent reference laboratories or hospital-based facilities. In the U.S., these central laboratories account for approximately 75% of the revenues generated by IVD products.Total revenues from the rapid, non-instrument-based professional POC market were estimated at approximately $483 million in 2005 in the U.S.
|
|
| Competitors / Substitutes / Alternatives |
Abbott Laboratories, Beckman Coulter Inc., Hemagen Diagnostics Inc.
|
|
| Status |
| Quidel plans on increasing its research and development efforts and accelerate the rate of new product introductions. The QuickVue iFOB (immunochemical Fecal Occult Blood) test was launched in 2006 for the qualitative detection of blood in stool which is an indication of a number of gastrointestinal disorders, including colorectal cancer. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
